• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (NQ:KNSA)

    59.55 +0.07 (+0.12%)
    Streaming Delayed Price Updated: 12:28 PM EDT, May 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

    < Previous 1 2 3 4 5 Next >
    News headline image
    Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today ↗
    The biotech delivered a beat-and-raise first quarter. 
    Via The Motley Fool
    Gapping stocks in Tuesday's session ↗
    Via Chartmill
    Kiniksa Pharmaceuticals (NASDAQ:KNSA) Surges on Q1 Earnings Beat and Raised ARCALYST Guidance ↗
    Via Chartmill
    Topics Earnings
    Kiniksa Pharmaceuticals (NASDAQ:KNSA) Surfaces as a GARP Opportunity with a Growth Rating of 8 ↗
    Via Chartmill
    News headline image
    What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge ↗
    This biotech innovator in inflammatory disease therapies reported a notable insider sale amid strong revenue growth and recent stock gains. 
    Via The Motley Fool
    Topics Regulatory Compliance
    Kiniksa Pharmaceuticals (NASDAQ:KNSA) Fits the Minervini Trend Template with High-Growth Momentum ↗
    Via Chartmill
    Kiniksa Pharmaceuticals (NASDAQ:KNSA) Presents a Compelling Growth and Technical Setup ↗
    Via Chartmill
    Kiniksa Pharmaceuticals (NASDAQ:KNSA) Presents a High-Growth Momentum Setup ↗
    Via Chartmill
    News headline image
    Kiniksa Pharmaceuticals (KNSA) Shows High Growth Momentum and Technical Breakout Potential ↗
    Kiniksa Pharmaceuticals (KNSA) exemplifies a high-growth momentum stock with strong fundamentals and a positive technical setup for potential breakout. 
    Via Chartmill
    Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Top GARP Investment ↗
    Via Chartmill
    Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shows Strong Growth and Bullish Chart Setup ↗
    Via Chartmill
    Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shows High-Growth Momentum and Strong Technical Setup ↗
    Via Chartmill
    Kiniksa Pharmaceuticals (NASDAQ:KNSA): A Prime Example of Affordable Growth (GARP) Investing ↗
    Via Chartmill
    Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Compelling Value Investment ↗
    Via Chartmill
    News headline image
    Kiniksa (KNSA) Q4 2025 Earnings Call Transcript ↗
    Kiniksa (KNSA) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    Kiniksa Pharmaceuticals (NASDAQ:KNSA) Combines Strong Growth with Bullish Technical Setup ↗
    Via Chartmill
    Kiniksa Pharmaceuticals (NASDAQ:KNSA) Combines High Growth Momentum with Strong Technical Setup ↗
    Via Chartmill
    News headline image
    Kiniksa Pharmaceuticals (NASDAQ:KNSA) Fits the High-Growth Momentum and Trend Template Strategy ↗
    KNSA stock meets Minervini's Trend Template with strong technicals and high-growth fundamentals, including surging EPS and revenue. 
    Via Chartmill
    News headline image
    Kiniksa (KNSA) Q3 2025 Earnings Call Transcript ↗
    Kiniksa (KNSA) Q3 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Combines Technical Strength and Fundamental Growth Momentum ↗
    KNSA stock shows strong technical momentum per the Minervini Trend Template and impressive fundamental growth with 421% EPS growth. 
    Via Chartmill
    News headline image
    Earnings Scheduled For October 28, 2025 ↗
     
    Via Benzinga
    News headline image
    What to Expect from Kiniksa Pharmaceuticals's Earnings ↗
     
    Via Benzinga
    News headline image
    5 Analysts Have This To Say About Kiniksa Pharmaceuticals ↗
     
    Via Benzinga
    News headline image
    Kiniksa Pharmaceuticals (NASDAQ:KNSA) Identified by High Growth Momentum and Minervini Trend Screen ↗
    Kiniksa Pharma (KNSA) is a high-growth momentum stock in a strong technical uptrend, with surging earnings and sales supporting its price advance. 
    Via Chartmill
    News headline image
    What Analysts Are Saying About Kiniksa Pharmaceuticals Stock ↗
    4 analysts have expressed a variety of opinions on Kiniksa Pharmaceuticals (NASDAQ: KNSA) over the past quarter, offering a diverse set of opinions from bullish to bearish. 
    Via Benzinga
    News headline image
    Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shows High-Growth Momentum and Strong Technical Setup ↗
    Kiniksa Pharmaceuticals (KNSA) shows explosive EPS growth of 483% and strong technicals, trading near 52-week highs in a consolidation pattern that suggests a potential breakout. 
    Via Chartmill
    News headline image
    Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Emerges as an Affordable Growth Opportunity ↗
    Kiniksa Pharmaceuticals (KNSA) offers strong growth potential at a reasonable valuation. With 125% EPS growth, no debt, and a forward P/E of 21.47, it's a compelling affordable growth stock. 
    Via Chartmill
    News headline image
    Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Top Affordable Growth Candidate ↗
    Kiniksa Pharma (KNSA) is a strong affordable growth stock with impressive revenue & EPS growth, a reasonable valuation, and a solid debt-free balance sheet. 
    Via Chartmill
    News headline image
    Kiniksa Pharmaceuticals (NASDAQ:KNSA) Exhibits High Growth Momentum and Technical Breakout Potential ↗
    Kiniksa Pharma (KNSA) shows strong earnings growth and a bullish technical setup, making it a high-growth momentum stock to watch for a potential breakout. 
    Via Chartmill
    News headline image
    KINIKSA PHARMACEUTICALS INTE (NASDAQ:KNSA): A Strong Growth Stock with a Positive Technical Breakout ↗
    Kiniksa Pharma (KNSA) is a strong growth stock with 125% EPS growth, a debt-free balance sheet, and a bullish technical breakout pattern. 
    Via Chartmill
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.